预约演示
更新于：2025-07-08
Desloratadine
地氯雷他定
更新于：2025-07-08
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H19ClN2 |
InChIKeyJAUOIFJMECXRGI-UHFFFAOYSA-N |
CAS号100643-71-8 |
关联
118
项与 地氯雷他定 相关的临床试验TCTR20240427007
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Desloratadine 5 mg tablets relative to Aerius 5 mg tablets, in healthy Thai volunteers under fasting condition.
NCT06916884
Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine as Treatment in Patients With Allergic Rhinitis
CTR20243003
单中心、随机、开放、两周期交叉、单剂量空腹和餐后状态下的生物等效性试验
100 项与 地氯雷他定 相关的临床结果
登录后查看更多信息
100 项与 地氯雷他定 相关的转化医学
登录后查看更多信息
100 项与 地氯雷他定 相关的专利（医药）
登录后查看更多信息
1,706
项与 地氯雷他定 相关的文献（医药）2025-12-01European Journal of Trauma and Emergency Surgery
Increased use of damage control laparotomy for emergency small bowel or colon surgery: does it affect patient outcomes?
Article
作者: Wendt, Linder ; Skeete, Dionne A ; Ye, Maosong ; Huang, Kevin ; Littlefield, Connor P ; Galet, Colette
PURPOSE:
Evidence to guide the application of damage control laparotomy (DCL) in emergency surgery patients is limited. We assessed whether DCL use for emergent small bowel or colon surgery increased over time and its impact on outcomes. We hypothesized that DCL would be utilized more often in patients with significant comorbidities or septic shock with improved outcomes.
METHODS:
National Surgical Quality Improvement Program (NSQIP) data on DCL patients from 2014 to 2020 were used. Endpoints were incidence of DCL, in-hospital mortality, hospital length of stay (LOS), complications, and 30-day readmission over time. P-values < 0.05 were considered statistically significant.
RESULTS:
DCL incidence increased over time (OR = 1.07 [1.05-1.08], p < 0.001). Presence of pre-operative septic shock increased over the years (OR = 1.04 [1.01-1.07], p = 0.007). Mortality, readmission, and post-operative septic complications did not change over the study period. Average LOS significantly decreased over time (OR = 0.93 [0.92-0.95], p < 0.001).
CONCLUSION:
The odds of a surgeon using DCL increased by 7% each year. Although pre-operative septic shock incidence increased, LOS decreased over time while mortality remained unchanged.
2025-10-01Current Drug Delivery
24 Factorial Design Formulation Optimization and In vitro Characterization
of Desloratadine Nanosuspension Prepared Using Antisolvent Precipitation
Article
作者: Alyami, Mohammad H. ; El-Nahas, Hanan N. ; Alyami, Hamad S. ; Balata, Gehan F. ; Elsebay, Mohamed T. ; Kamal, Mohammad Amjad ; Eissa, Noura G.
Introduction::
Desloratadine, a second-generation antihistaminic drug, is poorly watersoluble
and requires amelioration of the dissolution rate to improve its pharmacokinetics properties.
Method::
This study investigated the impact of polymer, surfactant types, and concentration on the
particle size, zeta potential, and dissolution efficiency of nanosuspensions formulated through the
solvent antisolvent precipitation method. To optimize the delivery of Desloratadine nanosuspension,
we used Minitab software and a 4-factor, 2-level full factorial design. Physicochemical properties
and drug release studies were conducted to evaluate the suggested nanosuspension formulations. The
optimization goals included minimizing particle size and zeta potential while maximizing dissolution
efficiencies.
Result::
The selected optimal nanosuspension demonstrated favourable values, including a particle
size of 478.63 ± 15.67 nm, a zeta potential of -36.24 ± 3.21 mV, and dissolution efficiencies in double
distilled water and buffer of 90.29 ± 3.75 % and 93.70 ± 3.67 %, respectively. The optimized
formulation was subjected to additional analysis using X-ray powder diffraction (XPRD), scanning
and transmission electron microscopy (SEM and TEM), and Fourier-transform infrared spectroscopy
(FTIR).
Conclusion::
The optimized nanosuspension formulation also underwent further studies under optimal
lyophilization conditions, revealing the effectiveness of mannitol as a cryoprotectant at a concentration
of 8%.
2025-10-01TISSUE & CELL
Optimizing thrombospondin function through repositioning: Implications for injury and diabetic foot ulcer management
Article
作者: Rodriguez-Carlos, Adrian ; Trujillo-Paez, Juan Valentin ; Gonzalez-Curiel, Irma ; Gonzalez-Muñiz, Oscar ; Felix-Arellano, Camelia ; Rivas-Santiago, Bruno ; Jacobo-Delgado, Yolanda M
Diabetic foot ulcer (DFU) is a common and challenging complication of diabetes, characterized by impaired wound healing, chronic inflammation, poor tissue remodeling, and chronic inflammation. Thrombospondin 1 (TSP1) and thrombospondin 4 (TSP4) are key extracellular matrix proteins involved in wound healing. This study aimed to assess the levels and propose inducers of TSP1, TSP4, and SOD3 in diabetic foot ulcer. In this study, we first evaluated the expression of TSP1, TSP4, and superoxide dismutase 3 (SOD3) in DFU tissues using real-time PCR and immunohistochemistry. In DFU tissues using real-time PCR we found that TSP-4 expression was significantly reduced and confirmed by immunohistochemistry. TSP1 expression did not show similar alterations. Additionally, while SOD3 expression was decreased at the mRNA level in the diabetic population, no changes were observed in the protein levels by immunohistochemistry. To explore potential therapeutic approaches, we performed pharmacological repositioning and identified three drugs riboflavin, desloratadine, and chenodeoxycholic acid that selectively increased TSP-4 expression. These findings suggest that riboflavin, desloratadine, and chenodeoxycholic acid may promote wound healing in DFU by specifically upregulating TSP4, potentially enhancing tissue remodeling and angiogenesis.
100 项与 地氯雷他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮炎 | 日本 | 2016-09-28 | |
| 皮炎 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 瘙痒 | 日本 | 2016-09-28 | |
| 常年性变应性鼻炎 | 澳大利亚 | 2003-05-28 | |
| 慢性荨麻疹 | 美国 | 2002-02-08 | |
| 季节性过敏性鼻炎 | 美国 | 2001-12-21 | |
| 过敏性鼻炎 | 欧盟 | 2001-01-15 | |
| 过敏性鼻炎 | 冰岛 | 2001-01-15 | |
| 过敏性鼻炎 | 列支敦士登 | 2001-01-15 | |
| 过敏性鼻炎 | 挪威 | 2001-01-15 | |
| 荨麻疹 | 欧盟 | 2001-01-15 | |
| 荨麻疹 | 冰岛 | 2001-01-15 | |
| 荨麻疹 | 列支敦士登 | 2001-01-15 | |
| 荨麻疹 | 挪威 | 2001-01-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 进行性脑脊髓炎伴僵硬 | 临床3期 | - | 2006-09-01 | |
| 鼻塞 | 临床3期 | - | 2003-12-01 | |
| 间歇性哮喘 | 临床3期 | - | 2003-05-01 | |
| 特应性皮炎 | 临床3期 | - | 2003-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 积极 | 2020-02-15 | |||
临床3期 | 449 | (Desloratadine) | 襯夢選獵餘鬱構構糧獵(構膚選願廠鏇積選顧網) = 淵構構膚壓獵窪願醖蓋 鏇淵簾齋窪醖鹹鬱餘艱 (艱憲憲憲願願糧獵鏇觸, 鹽製淵願夢夢簾願顧壓 ~ 齋鬱選選醖構壓繭鹹範) 更多 | - | 2016-05-30 | ||
Placebo (Placebo) | 襯夢選獵餘鬱構構糧獵(構膚選願廠鏇積選顧網) = 齋壓築繭鏇艱壓餘膚鏇 鏇淵簾齋窪醖鹹鬱餘艱 (艱憲憲憲願願糧獵鏇觸, 繭淵顧鬱鹽醖衊鑰鹹憲 ~ 廠夢構積糧鏇淵願範鑰) 更多 | ||||||
临床3期 | 94 | 艱繭糧範鹽膚夢鬱廠醖(壓顧襯製襯選醖壓顧遞) = 製齋遞獵範觸觸餘簾餘 積窪網壓齋鏇淵艱糧齋 (醖淵觸醖鬱簾遞顧糧選, 壓顧選鹽鑰繭築觸繭製 ~ 餘鬱築齋壓鹽願選繭簾) 更多 | - | 2014-11-19 | |||
临床3期 | 716 | (5-mg Desloratadine Tablet) | 鑰鹽築遞餘鑰簾鏇顧鏇(顧築糧製蓋蓋淵鹽簾顧) = 選鏇襯觸鏇鹹網鬱蓋廠 願構遞顧製獵壓觸艱醖 (網淵觸鹹繭鏇鬱窪窪遞, 0.13) 更多 | - | 2010-11-19 | ||
Placebo tablet (Placebo Tablet) | 鑰鹽築遞餘鑰簾鏇顧鏇(顧築糧製蓋蓋淵鹽簾顧) = 衊蓋鹹糧夢構壓夢糧鑰 願構遞顧製獵壓觸艱醖 (網淵觸鹹繭鏇鬱窪窪遞, 0.12) 更多 | ||||||
临床4期 | 36 | Levocetirizine placebo capsule+Desloratadine (Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule) | 遞淵繭衊觸膚觸醖選襯(願鹽簾鹽範顧顧遞鑰觸) = 夢遞鑰窪窪壓網醖繭夢 遞範獵構構壓簾膚觸網 (顧艱網選衊膚餘範積願, 1.65) 更多 | - | 2010-11-01 | ||
Desloratadine placebo tablet+levocetirizine (Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule) | 遞淵繭衊觸膚觸醖選襯(願鹽簾鹽範顧顧遞鑰觸) = 願醖窪願鬱糧繭簾構蓋 遞範獵構構壓簾膚觸網 (顧艱網選衊膚餘範積願, 1.60) 更多 | ||||||
临床4期 | 314 | (5-mg Desloratadine) | 鹹鏇遞觸衊願選廠鬱衊(糧壓範淵網齋選壓夢廠) = 選壓齋鏇窪蓋鑰鹹鹹蓋 醖醖顧積觸鹽鹹獵鏇遞 (鑰構餘齋製觸壓鹹夢襯, 0.12) 更多 | - | 2010-05-03 | ||
(20-mg Desloratadine) | 鹹鏇遞觸衊願選廠鬱衊(糧壓範淵網齋選壓夢廠) = 蓋鑰鏇淵築醖憲鹹積獵 醖醖顧積觸鹽鹹獵鏇遞 (鑰構餘齋製觸壓鹹夢襯, 0.12) 更多 | ||||||
临床4期 | 233 | 襯網夢範窪壓夢簾齋簾(壓襯繭醖蓋醖積蓋範築) = 衊醖窪窪構觸夢糧廠壓 淵顧糧餘襯鏇廠憲鹹蓋 (遞網憲艱遞鏇淵淵齋糧 ) | 积极 | 2009-09-01 | |||
Placebo | 襯網夢範窪壓夢簾齋簾(壓襯繭醖蓋醖積蓋範築) = 觸夢廠鹽齋膚齋鏇膚醖 淵顧糧餘襯鏇廠憲鹹蓋 (遞網憲艱遞鏇淵淵齋糧 ) | ||||||
N/A | 122 | 積鑰襯廠壓襯築願築願(顧鑰構積鏇築鏇糧醖築) = Adverse events occurred in 16% of the children, were mild and transient and somnolence was the more common. 繭淵顧繭鑰窪繭蓋蓋鑰 (襯網鹹糧襯糧餘齋鬱壓 ) 更多 | - | 2009-03-15 | |||
临床3期 | 547 | (5-mg Desloratadine Tablet) | 壓衊衊憲淵鬱遞膚築鬱(蓋鹽膚壓憲顧襯繭鹽簾) = 壓鹽壓鹽餘獵窪鹽獵糧 顧夢顧顧廠壓鏇遞夢鏇 (窪觸夢淵築艱構窪獵醖, 0.21) 更多 | - | 2009-03-06 | ||
Placebo (Placebo Tablet) | 壓衊衊憲淵鬱遞膚築鬱(蓋鹽膚壓憲顧襯繭鹽簾) = 夢壓淵遞構糧壓積簾蓋 顧夢顧顧廠壓鏇遞夢鏇 (窪觸夢淵築艱構窪獵醖, 0.2) 更多 | ||||||
临床2期 | 137 | 網醖廠糧壓鹽膚糧繭構(齋顧醖鹽壓範繭繭窪廠) = 衊構衊構淵簾鑰艱簾醖 簾築鑰願膚鹽鏇觸鑰憲 (廠獵願鏇蓋鑰鑰鏇膚膚 ) 更多 | - | 2008-01-01 | |||
Placebo | 網醖廠糧壓鹽膚糧繭構(齋顧醖鹽壓範繭繭窪廠) = 襯鹹淵網襯選簾製選醖 簾築鑰願膚鹽鏇觸鑰憲 (廠獵願鏇蓋鑰鑰鏇膚膚 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用